Fibrocell Science makes board appointment
This article was originally published in Scrip
Executive Summary
Fibrocell Science (US), a biotechnology company focused on the development of regenerative fibroblast cell therapy for aesthetic, medical and scientific applications, has appointed Marc Mazur to its board of directors. He is the chairman of the London-based equity hedge fund Elsworthy Capital Management.